This is a material catalyst for MNKD — Afrezza's only marketed product now has a major label expansion into a large, needle-averse pediatric population. Traders should watch for prescription volume data over the next 2-4 quarters as a read on commercial uptake. The stock may gap up significantly on this news given the $1.1B market cap and largely adult-only revenue base prior to approval.
Price Chart
Executive Summary
MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabetes. This expands Afrezza's addressable population by >350,000 US children/adolescents with diabetes and represents a significant label expansion for MannKind's only marketed product. The approval is based on the Phase 3 INHALE-1 trial and 20+ years of safety data.
Key Facts
- FDA approved Afrezza for children/adolescents aged 6+ with type 1 and type 2 diabetes
- Over 350,000 US children/adolescents have diabetes, mostly type 1 requiring lifelong insulin
- Approval supported by Phase 3 INHALE-1 trial and 20+ years of clinical data
- Eligible patients pay $35/month or less through MannKind Cares
- Afrezza is the only ultra rapid-acting inhaled insulin and was previously approved only for adults (2014)
Financial Impact
Expands TAM by ~350K pediatric diabetes patients in the US; current MNKD market cap ~$1.1B. The pediatric approval likely adds $100-300M+ in peak revenue opportunity (based on typical inhaled insulin penetration) but exact figures are not stated.
Risk Factors
- Afrezza's commercial adoption in adults has been slow since 2014 launch; pediatric uptake may face similar barriers
- Competing with entrenched injectable insulin analogs and pumps; insurance coverage/reimbursement challenges
- Potential lung function concerns in growing children — long-term safety data are limited
- Black-box warning for bronchospasm in patients with chronic lung disease limits target population
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303734 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.74 (−2.86%) |
Jul 24, 2026 9w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.74 (−5.32%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.74 (−6.03%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.74 (+11.31%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.74 (+9.04%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.74 (−0.80%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.74 (+2.75%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.74 (+5.35%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.74 (+14.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access